Results 31 to 40 of about 48,636 (248)

Heterologous immunity revisited

Parasitology, 2001
Heterologous immunity, or protection by one invading organism against another across phylogenetic divides, has been recognised for decades. It was initially thought to operate largely through enhancement of phagocytosis, but this explanation became untenable when it was realised it worked extremely well against intraerythrocytic protozoa and killed ...
openaire   +2 more sources

Pathogenic epitopes, heterologous immunity and vaccine design [PDF]

Nature Reviews Microbiology, 2007
Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic.
Welsh, Raymond M., Fujinami, Robert S.
openaire   +2 more sources

Heterologous autoimmunity and prokaryotic immune defense [PDF]

, 2021
Some prokaryotes possess CRISPR-Cas systems that provide adaptive immunity to viruses guided by DNA segments called spacers acquired from invading phage. However, the patchy incidence and limited memory breadth of CRISPR-Cas systems suggest that their fitness benefits are offset by costs.
Hanrong Chen, Andreas Mayer, Vijay Balasubramanian   +2 more
openaire   +2 more sources

Past Life and Future Effects—How Heterologous Infections Alter Immunity to Influenza Viruses

Frontiers in Immunology, 2018
Influenza virus frequently mutates due to its error-prone polymerase. This feature contributes to influenza virus’s ability to evade pre-existing immunity, leading to annual epidemics and periodic pandemics.
Aisha Souquette, Paul G. Thomas
doaj   +1 more source

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

Frontiers in Immunology, 2023
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines.
Larissa Henze, Larissa Henze, Julian Braun, Julian Braun, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Karsten Jürchott, Karsten Jürchott, Maike Schlotz, Janine Michel, Marica Grossegesse, Maike Mangold, Maike Mangold, Manuela Dingeldey, Manuela Dingeldey, Beate Kruse, Beate Kruse, Pavlo Holenya, Norbert Mages, Norbert Mages, Norbert Mages, Ulf Reimer, Maren Eckey, Karsten Schnatbaum, Holger Wenschuh, Bernd Timmermann, Florian Klein, Florian Klein, Florian Klein, Andreas Nitsche, Claudia Giesecke-Thiel, Lucie Loyal, Lucie Loyal, Andreas Thiel, Andreas Thiel   +36 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review

Frontiers in Immunology
IntroductionBCG vaccination can have heterologous or non-specific effects (NSE) that confer resistance against pathogens other than its target Mycobacterium tuberculosis, but the underlying mechanisms are not fully understood.MethodsWe conducted a ...
Louis Torracinta, Nino Gogichadze, Rachel Tanner   +2 more
doaj   +1 more source

Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity

mBio, 2015
The continual threat to global health posed by influenza has led to increased efforts to improve the effectiveness of influenza vaccines for use in epidemics and pandemics.
Brendon Y. Chua, Chinn Yi Wong, Edin J. Mifsud, Kathryn M. Edenborough, Toshiki Sekiya, Amabel C. L. Tan, Francesca Mercuri, Steve Rockman, Weisan Chen, Stephen J. Turner, Peter C. Doherty, Anne Kelso, Lorena E. Brown, David C. Jackson   +13 more
doaj   +1 more source

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

npj Vaccines, 2022
The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity.
Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn   +7 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source